| Identification | Back Directory | [Name]
PRT062607 (Hydrochloride) | [CAS]
1370261-97-4 | [Synonyms]
CS-995
BIIB057 HCl
PRT-2607 HCl
PRT062607 HCL
P505-15 hydrochloride
PRT062607 (P505-15 HCL)
PRT062607 (Hydrochloride)
PRT062607 (P505-15, BIIB057) HCl
PRT062607 (Hydrochloride) USP/EP/BP
P505-15, BIIB057 HCl, PRT062607(HCL)
PRT062607 (P505-15, BIIB057) hydrochloride
P505-15 HCl salt, PRT062607 HCl salt,PRT-2607 HCl salt, BIIB-057 HCl salt
P505-15; PRT2607; PRT-2607; PRT 2607; PRT-062607; PRT 062607; P505-15; BIIB057
4-((4-(2H-1,2,3-Triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-ca
2-[[(1R,2S)-2-AMinocyclohexyl]aMino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]aMino]-5-pyriMidinecarboxaMide Hydrochloride
4-((4-(2H-1,2,3-Triazol-2-yl)phenyl)amino)-2-(((1R,2S)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride
2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide hydrochloride (1:1)
5-Pyrimidinecarboxamide, 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-, hydrochloride (1:1)
2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide hydrochloride (1:1)
PRT062607 (P505-15, BIIB057) HCl | [Molecular Formula]
C19H24ClN9O | [MDL Number]
MFCD28142764 | [MOL File]
1370261-97-4.mol | [Molecular Weight]
429.907 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
≥21.5 mg/mL in DMSO; insoluble in EtOH; ≥83.2 mg/mL in H2O with gentle warming | [form ]
solid | [color ]
Light yellow to khaki |
| Hazard Information | Back Directory | [Uses]
PRT062607 (Hydrochloride)acts as a novel spleen tyrosine kinase (syk) inhibitors used in the treatment of leukemia.
| [in vivo]
PRT062607 Hydrochloride produced dose-dependent anti-inflammatory activity in two rodent models of rheumatoid arthritis. PRT062607 Hydrochloride (15, 30 mg/kg; po; bid; 5 d) causes SYK inhibition in mice and prevents BCR-induced splenomegaly in mice[1].
PRT062607 Hydrochloride (15 mg/kg; po ; bid; 5 d) SYK inhibition in mice prevents Ramos tumor formation in mouse xenograft models[1].
PRT062607 Hydrochloride (10-20 mg/kg; po; bid, ) prevents BCR mediated splenomegaly and significantly inhibited NHL tumor growth in xenograft models[2].
| Animal Model: | anti-IgD Stimulated Mouse Inflammation Model[1] | | Dosage: | 10 mg/kg, 15 mg/kg, 20 mg/kg | | Administration: | po; bid for 5 days | | Result: | Suppressed mouse B-cell activation following stimulation with this anti-IgD.
|
| Animal Model: | Ramos Tumor Xenograft Model in NOD/SCID mice[1] | | Dosage: | 15 mg/kg, 30 mg/kg | | Administration: | po; bid; terminated when tumor weights began reaching approximately 1.5 mg, at which time tumors were excised and weighed. | | Result: | Protected mouse from Ramos tumor growth in vivo. |
| [target]
Syk | [IC 50]
Lck: 249 nM (IC50, [2]); PAK5: 166 nM (IC50, [2]) | [storage]
Store at -20°C |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|